Zhengye Biotechnology Holding Limited Class A Ordinary Shares (ZYBT)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the 2026-10-26 close of $1.42, Zhengye carries a $43.6 million market cap, so I am looking at a very small veterinary-vaccine business with only 269 employees. The FairStock figures show a P/E of -6.45 and a P/B of 1.82; paying above book for a loss-maker is not a Graham-style bargain unless future earning power is proven. Returns are poor: ROE is -25.17% and ROCE is -9.48%. Debt-to-equity of 0.24 is not alarming, but the Altman Z-score of 0.18 and Piotroski F-score of 1/9 describe a fragile financial position rather than a fortress. The 52-week range of $0.62 to $8.01 also tells me the market has swung wildly around this tiny equity. The business sells vaccines for swine, cattle, goats, sheep, poultry and dogs in China, which is a specialized niche, but I see no multi-year record here. FairStock assigns no Lynch category because there are only 0 years of filed results; revenue growth and profit growth are N/A. Without a durable earnings history, I cannot establish a margin of safety from the income statement, and the FairStock score of 44/100 is middling at best. Book value may offer some reference at P/B 1.82, but book value is not a floor when returns are negative and Altman is weak. My conclusion is that this is a speculative micro-cap, not a proven compounding business; the price is not demonstrably cheap on the supplied numbers.

In plain English: Zhengye Biotechnology makes veterinary vaccines for livestock and pets in China. The numbers provided show a weak business: it is losing money, earning negative returns, and has very little filed history to judge. At $1.42, it does not look clearly cheap; without positive profits, the price looks speculative rather than a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer